tbuckley/cabot-search huggingface dataset:
Reply
Authors: Jun‐feng Chen, Bing‐liang Lin
Journal: Hepatology (2018)

Firstly, thank you very much for the valuable suggestions on our article. Our reply is as follows. In our preliminary experiment, we divided patients into three groups, 10 patients in each group. Group A received standard medicine treatment (SMT) only. Group B was treated with allogeneic bone marrow‐derived mesenchymal stem cells (BM‐MSCs) every week for 4 weeks, at a dosage of 1 × 105/kg. For group C the dosage of BM‐MSCs was 10 × 106/kg. No significant difference was found in the levels of liver function and 24‐week survival rate between groups B and C (data not published). This may be related to the peripheral vein infusion. Therefore, in our formal study we did not conduct a subgroup analysis. In our study, we infused BM‐MSCs through the peripheral vein for the following reasons. (1) Systemic inflammatory reactions play a key role in the development of acute‐on‐chronic liver failure (ACLF).(1) BM‐MSCs regulate immunity through paracrine mechanisms.(2) (2) ACLF patients have coagulation disorders, and infusion of BM‐MSCs through the hepatic artery has a risk of hemorrhage. Therefore, we speculated that intravenous infusion might be a better delivery method for ACLF patients. Lastly, the best source of MSCs is unclear. Some studies have shown that bone marrow has better proliferative potential.(3) Recently, a pooled analysis showed that "bone marrow‐derived MSCs are optimal in terms of improving liver function."(4) We considered that a large‐scale, randomized, controlled trial is still needed to compare the efficacy between BM‐MSCs and umbilical cord–derived MSCs for ACLF patients. A comprehensive assessment is needed to study the benefits of these two sources of MSCs for ACLF patients. Thanks again for your valuable suggestions. Potential conflict of interest Nothing to report.
The epidemiology of trauma and post-traumatic stress disorder in a representative cohort of young people in England and Wales
Authors: Stephanie J Lewis, Louise Arseneault, Avshalom Caspi, Helen L Fisher, Timothy Matthews, Terrie E Moffitt, Candice L Odgers, Daniel Stahl, Jia Ying Teng, Andrea Danese
Journal: The Lancet Psychiatry (2019)

Despite the emphasis placed on childhood trauma in psychiatry, comparatively little is known about the epidemiology of trauma and trauma-related psychopathology in young people. We therefore aimed to evaluate the prevalence, clinical features, and risk factors associated with trauma exposure and post-traumatic stress disorder (PTSD) in young people.
Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors
Authors: Jonathan M. Cooper, Amish J. Patel, Zhiguo Chen, Chung-Ping Liao, Kun Chen, Juan Mo, Yong Wang, Lu Q. Le
Journal: Clinical Cancer Research (2019)

Abstract Purpose: BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in preclinical studies, including neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST. Experimental Design: Through modeling tumor evolution by studying genetic changes underlying the development of MPNST, a lethal sarcoma with no effective medical treatment, we identified a targetable addiction to BET bromodomain family member BRD4 in MPNST. This served as a controlled model system to delineate mechanisms of sensitivity and resistance to BET bromodomain inhibitors in this disease. Results: Here, we show that a malignant progression–associated increase in BRD4 protein levels corresponds to partial sensitivity to BET inhibition in MPNST. Strikingly, genetic depletion of BRD4 protein levels synergistically sensitized MPNST cells to diverse BET inhibitors in culture and in vivo. Conclusions: Collectively, MPNST sensitivity to combination genetic and pharmacologic inhibition of BRD4 revealed the presence of a unique addiction to BRD4 in MPNST. Our discovery that a synthetic lethality exists between BET inhibition and reduced BRD4 protein levels nominates MPNST for the investigation of emerging therapeutic interventions such as proteolysis-targeting chimeras (PROTACs) that simultaneously target bromodomain activity and BET protein abundance.
Origin and evolution of the octoploid strawberry genome
Authors: Patrick P. Edger, Thomas J. Poorten, Robert VanBuren, Michael A. Hardigan, Marivi Colle, Michael R. McKain, Ronald D. Smith, Scott J. Teresi, Andrew D. L. Nelson, Ching Man Wai, Elizabeth I. Alger, Kevin A. Bird, Alan E. Yocca, Nathan Pumplin, Shujun Ou, Gil Ben-Zvi, Avital Brodt, Kobi Baruch, Thomas Swale, Lily Shiue, Charlotte B. Acharya, Glenn S. Cole, Jeffrey P. Mower, Kevin L. Childs, Ning Jiang, Eric Lyons, Michael Freeling, Joshua R. Puzey, Steven J. Knapp
Journal: Nature Genetics (2019)

Cultivated strawberry emerged from the hybridization of two wild octoploid species, both descendants from the merger of four diploid progenitor species into a single nucleus more than 1 million years ago. Here we report a near-complete chromosome-scale assembly for cultivated octoploid strawberry (Fragaria × ananassa) and uncovered the origin and evolutionary processes that shaped this complex allopolyploid. We identified the extant relatives of each diploid progenitor species and provide support for the North American origin of octoploid strawberry. We examined the dynamics among the four subgenomes in octoploid strawberry and uncovered the presence of a single dominant subgenome with significantly greater gene content, gene expression abundance, and biased exchanges between homoeologous chromosomes, as compared with the other subgenomes. Pathway analysis showed that certain metabolomic and disease-resistance traits are largely controlled by the dominant subgenome. These findings and the reference genome should serve as a powerful platform for future evolutionary studies and enable molecular breeding in strawberry.
Artificial intelligence and colonoscopy: the time is ripe to begin clinical trials
Authors: Yuichi Mori
Journal: Endoscopy (2019)

Recently, increased attention has been paid to optical biopsy modalities for diagnosing colorectal polyps. To reduce the cost of unnecessary polypectomies and/or pathological assessments of diminutive colorectal polyps (≤ 5 mm), adopting optical diagnoses based on an advanced endoscopic modality with high confidence prediction has been proposed as an alternative to histopathology by both the European Society of Gastrointestinal Endoscopy (ESGE) [1] and the American Society for Gastrointestinal Endoscopy [2]. However, to adhere to this initiative, endoscopists must exceed the performance thresholds for optical biopsy: > 90 % negative predictive value for identifying diminutive rectosigmoid adenomas is required to conduct "diagnose-and-leave" hyperplastic polyps, which is known as the Preservation and Incorporation of Valuable Endoscopic Innovations initiative-2 [PIVI-2]) [2]. However, these thresholds can only be met by experts and intensively trained endoscopists [3]. Standardized accreditation together with the auditing of endoscopists' performance are also needed to put optical biopsy to practical use [4], and this has hindered its widespread use in routine colonoscopies.
Improving the evidence base for social prescribing
Authors: Kate E Hamilton-West, Erica Gadsby, Sarah Hotham
Journal: BMJ (2019)

Salisbury’s article raises important points about the widespread rollout of social prescribing.1 Linking people with services that could help tackle problems that contribute to reduced wellbeing seems sensible, but the approach rests on several problematic assumptions.

A recent systematic review2 concluded that current evidence on social prescribing is insufficient to judge either success or value for money. Of the 15 …
Long Term AML Survivors Have Increased Mortality and High Prevalence of Clonal Hematopoiesis
Authors: Noa Chapal Ilani, Elisabeth Niemeyer, Netta Mendelson Cohen, Yoni Moskovitz, Barak Oron, Amanda Mitchell, Mark D. Minden, Amos Tanay, Ran Balicer, Tamir Biezuner, Daniela Cilloni, Klaus H. Metzeler, Yishai Ofran, Nathali Kaushansky, Liran I. Shlush
Journal: Blood (2018)
Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials
Authors: Bettina Altmann, Gerald Wulf, Lorenz Truemper, Francesco d'Amore, Thomas Relander, Helle Toldbod, Jan M.A. Delabie, Andreas Rosenwald, Marita Ziepert, Markus Loeffler
Journal: Blood (2018)
P104 Anaeroplasma, a potential anti-inflammatory probiotic for the treatment of chronic intestinal inflammation
Authors: A Beller, A Kruglov, P Durek, V von Goetze, U Hoffmann, R Maier, K Heiking, B Siegmund, GA Heinz, M-F Mashreghi, A Radbruch, H-D Chang
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Post-doctoral fellow. <h3>Introduction</h3> The human intestine is colonized with billions of microorganisms, which form the gut microbiota, consisting of up to 1000 different bacterial species. Recent studies have implicated the intestinal microbiota in the pathogenesis of chronic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, and Sjögren's syndrome. Yet, we still lack the knowledge which bacteria of the gut microbiota induce, promote or inhibit chronic inflammatory inflammation. <h3>Objectives</h3> The aim of our work is to identify members of the intestinal microbiota with pro- or anti-inflammatory properties for targeted and therapeutic manipulation of the microbiota in chronic inflammatory diseases. <h3>Methods</h3> We have developed high-resolution microbiota flow cytometry which allows us to analyze the microbiota on a single cell level. This provides a non-invasive, fast and efficient diagnostic tool to visualize dramatic changes of microbiota composition in inflammatory diseases, fast and efficiently, and isolate distinct bacteria for functional and molecular analyses. <h3>Results</h3> We have identified bacteria belonging to the genus Anaeroplasma, which enhances the levels of mucosal IgA. Adoptive transfer of Anaeroplasma increases the numbers of IgA+ germinal center B cells in the Peyer's patches and of IgA-secreting plasma cells in the lamina propria of the small intestine leading to significantly enhanced mucosal IgA levels. <i>Anaeroplasma</i> controls IgA expression presumably its ability to induce expression of the regulatory cytokine TGF-β in T cells, as we show here. <h3>Conclusions</h3> The anti-inflammatory properties of <i>Anaeroplasma</i> to induce the anti-inflammatory cytokine TGF-β, thereby also strengthening the intestinal barrier by enhancing mucosal IgA, qualify <i>Anaeroplasma</i> as potent probiotic for the prevention and treatment of chronic inflammation. <h3>Disclosure of Interest</h3> None declared.
Health of London during the Six Months terminating September 27, 1851
Authors: J. Webster
Journal: BMJ (1851)

CONSIDERING the recent enormous and constantly changing population collected in London dunrng the period to which this report refers, from all parts of the empire, and from foreign countries, it is particularly interesting to ascertain, how far the sanitary condition of the capital manifested any difference from that of the corresponding period of previous or ordinary years ?The inquiry is highly important, alike to the political economist and to the physician.With the view of supplying evidence whereon to found deductions respecting several vital questions, I now proceed, in accordance with the method I have hitherto adopted; first, to enumerate the gross amount of deaths re- corded throughout the metropolitan districts during the half year ending the 27th of last September; and afterwards, to give a few details illustrating the varied mortality produced by particular maladies, in order thereby to point out wherein recent results differed from, or resembled, those met with during the parallel six months of the pre- vious year.The health of the metropolis during the past summer and autumn, although in some respects not so satisfactory as throughout the same months of the year 1850, has not been remarkable either for the severity of prevalent diseases, or on account of its aggregate mortality.During the six months terminating on the 27th of last September, the total deaths amounted to 25,980, contradistinguished to 22,816 during the parallel period of 1850, thus making an increase of 3,164.However, it should be remembered, the majority of deaths took place during the first three months of the recent half year, when 1,845 more deaths were recorded than the number which occurred during the same quarter of 1850; but the excess was only 148 beyond the nuimber VOL.ITT.
Doctors call on UK to be carbon neutral by 2030
Authors: Harriet Pike
Journal: BMJ (2019)

Health professionals from a range of disciplines have called on UK parliamentarians to legislate urgently for the UK to be carbon neutral by 2030.

In an open letter published in The BMJ and the Lancet on 21 February,12 the group asks that laws be brought in to allow the UK to reduce its carbon emissions to net zero levels over the next decade.

The signatories, headed by Robin Stott, co-chair of the Climate and Health Council and a board member of the UK Health Alliance on Climate Change, warn that the climate crisis has reached a new level of severity, with “increasingly forceful statements” from the Intergovernmental Panel …
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Authors: Alexander C. Huang, Robert J. Orlowski, Xiaowei Xu, Rosemarie Mick, Sangeeth M. George, Patrick K. Yan, Sasikanth Manne, Adam A. Kraya, Bradley Wubbenhorst, Liza Dorfman, Kurt D’Andrea, Brandon M. Wenz, Shujing Liu, Lakshmi Chilukuri, Andrew Kozlov, Mary Carberry, Lydia Giles, Melanie W. Kier, Felix Quagliarello, Suzanne McGettigan, Kristin Kreider, Lakshmanan Annamalai, Qing Zhao, Robin Mogg, Wei Xu, Wendy M. Blumenschein, Jennifer H. Yearley, Gerald P. Linette, Ravi K. Amaravadi, Lynn M. Schuchter, Ramin S. Herati, Bertram Bengsch, Katherine L. Nathanson, Michael D. Farwell, Giorgos C. Karakousis, E. John Wherry, Tara C. Mitchell
Journal: Nature Medicine (2019)
Expulsion from medical society. 2
Authors: A. R. Holder
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of the activating Kit mutation D816V in laser capture microdissected mast cells and lymphoid cells from bone marrow biopsy tissues from patients with mastocytosis
Authors: M. L. Taylor, D. Sehgal, R. G. Mage, M. Raffeld, C. Akin, D. D. Metcalfe
Journal: Journal of Allergy and Clinical Immunology (2001)
Opioid Dependency Significantly Increases Complications and Mortality in Sickle Cell Disease
Authors: Stuthi Pavani Perimbeti, Kevin Ye Hou, Sabarina Ramanathan, Adonas Woodard, Daniel Kyung, Priyadarshini Pathak, Rishi Shrivastav, Kristine Ward, Michael Styler
Journal: Blood (2018)
Abstract 4294: Copper is required for oncogenic BRAF signaling and tumorigenesis.
Authors: Donita C. Brady, Matthew S. Crowe, Michelle L. Turski, Dennis J. Thiele, Christopher M. Counter
Journal: Cancer Research (2013)

Abstract The BRAF serine/threonine kinase is mutated, typically at V600, to remain in the active oncogenic state in a large fraction of melanoma, thyroid cancers, and hairy cell leukemia, and to a lesser extent in a wide spectrum of other cancers, thereby activating the kinases MEK1 and MEK2 to stimulate the MAPK pathway and promote cancer. Excitingly, ATP inhibitors of oncogenic BRAF and MEK provide a survival advantage in metastatic melanoma and early clinical studies suggest that coupling BRAF and MEK kinase inhibitors may be even more effective. Thus, the combination of multiple approaches to inhibit MAPK signaling holds great promise for the treatment of BRAF mutation-positive cancers, especially in terms of overcoming resistance. In this regard, we previously found that copper (Cu) influx enhanced MEK1 phosphorylation of its substrates ERK1/2 through a Cu-MEK1 interaction. We show here that genetic loss of the high affinity Cu transporter Ctr1 or mutations in MEK1 that disrupt Cu binding reduced MAPK signaling and oncogenic BRAFV600E-mediated tumorigenesis, which could be rescued by expressing activated ERK2. Importantly, a Cu chelator used in the treatment of Wilson's disease reduced tumor growth of not only BRAFV600E-transformed cells, but also cells resistant to a BRAF inhibitor. Taken together, these results suggest that Cu-chelation therapy could be repurposed for the treatment of BRAFV600E mutation-positive cancers. Citation Format: Donita C. Brady, Matthew S. Crowe, Michelle L. Turski, Dennis J. Thiele, Christopher M. Counter. Copper is required for oncogenic BRAF signaling and tumorigenesis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4294. doi:10.1158/1538-7445.AM2013-4294
Medical Schools in the United States, 2012-2013
Authors: Barbara Barzansky, Sylvia I. Etzel
Journal: JAMA (2013)

Thefollowingtablescontaindata thatarederivedmainly fromthe2012-2013LiaisonCommitteeonMedicalEducation(LCME)AnnualMedicalSchoolQuestionnairePart II. The questionnairewas sent in February 2013 to the deans of the136LCME-accreditedmedicalschoolswithenrolledstudents. Therewasa100%responserate.Eachquestionnairewasreviewed andattemptsweremade toverify informationandobtainmissingdata.Data foryearsother than2012-2013wereobtainedfrom previous LCMEAnnualMedical School Questionnaires. Author Affiliations:Medical Education Group, AmericanMedical Association, Chicago, Illinois. Corresponding Author: Barbara Barzansky, PhD, Division of Undergraduate Medical Education, AmericanMedical Association, 330 NWabash Ave, Chicago, IL 60611 (barbara.barzansky@ama-assn.org). Conflict of Interest Disclosures: The authors have completed and submitted the ICMJEFormforDisclosureofPotentialConflictsof Interestandnonewere reported. Funding/Support: This research was funded solely by the AmericanMedical Association, which employs Dr Barzansky andMs Etzel.
A resistance-sensing mechanical injector for the precise delivery of liquids to target tissue
Authors: Girish D. Chitnis, Mohan K. S. Verma, Julien Lamazouade, Miguel Gonzalez-Andrades, Kisuk Yang, Ali Dergham, Peter Anthony Jones, Benjamin E. Mead, Andrea Cruzat, Zhixiang Tong, Keir Martyn, Aniruddh Solanki, Natalie Landon-Brace, Jeffrey M. Karp
Journal: Nature Biomedical Engineering (2019)
Adverse effects on hematologic recovery after allogeneic bone marrow transplantation
Authors: Frederico Luiz Dulley, C M Massumoto, Pedro Enrique Dorlhiac Llacer, S F Hassan, Eduardo Massad, H A Loterio, J M M Gomes Filho, B Beitler, R C T Aguiar, Dalton de Alencar Fischer Chamone
Journal: Blood (1990)
Interaction between nitric oxide and neurokinins in modulation of distal airway eosinophilic inflammation: diferences in inflammatory cell expression of nNOS and iNOS
Authors: C. M. Prado, E. A. Leick Maldonado, V. Arata, D. I. Kasahara, F. T. Fernandes, M. A. Martins, I. F. L. C. Tiberio
Journal: American Journal of Respiratory and Critical Care Medicine (2003)
SP0152 Advanced Case Presentations: Interaction and Discussion
Authors: R. G. W. Lambert
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> A series of cases will be presented that highlight and emphasize the important points of MRI interpretation of the manifestations of arthritis. This will include both frequent and unusual MRI findings encountered in common clinical conditions and typical, though often misunderstood, capabilities and limitations of MRI. Audience participation will be incorporated throughout this presentation. <h3>Disclosure of Interest</h3> R. Lambert Consultant for: AbbVie and Synarc
Abstract 1979: Regulation of the oncogene ZNF217 by localization in breast cancer
Authors: Matthew J. Messana, Laurie E. Littlepage
Journal: Cancer Research (2015)

Abstract Poor prognosis in breast cancer patients occurs when malignant tumors adapt to environmental insults, become resistant to chemotherapy, evade immune surveillance and metastasize to other tissues. Tumors are thought to arise from individual cells with multiple mutations, including amplification of genomic regions that provide a growth advantage. A region on human chromosome 20 called 20q13 is increased in ∼25% of early stage human breast cancers and correlates with poor prognosis in patients. We have studied a novel oncogene ZNF217 within this region. ZNF217 is key in promoting breast cancer: it is not only a prognostic indicator of breast cancer progression in patients who have the worst prognosis but also is itself a drug target and/or marker of patient response to therapy. We find that ZNF217 protein is expressed most strongly in a small subset of cells within normal mammary epithelium and localizes predominantly in the nucleus of mammary epithelial cells. In contrast, the localization of ZNF217 is heterogeneous in breast tumors, with localization in both the nucleus and cytoplasm. Moreover, a truncated form of the protein localizes exclusively in the cytoplasm. We hypothesize that ZNF217 cytoplasmic localization affects ZNF217 function during cancer progression and can be used to predict poor prognosis in breast cancer patients. We have stained human breast tissue and human mammary epithelial cells for ZNF217 and find heterogeneous localization of ZNF217 across the samples. We now will identify the regions of ZNF217 that are required for ZNF217 localization in the nucleus and cytoplasm. We will utilize integrated biological approaches to determine the consequences of mis-localization of ZNF217 on cancer progression. Using our truncation mutants, we will determine which regions of ZNF217 are required for oncogenesis by overexpressing ZNF217 truncations in mammary epithelial cells and using these cells in a variety of assays that model steps in cancer progression assays that have previously shown that ZNF217 promotes cancer progression. Citation Format: Matthew J. Messana, Laurie E. Littlepage. Regulation of the oncogene ZNF217 by localization in breast cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1979. doi:10.1158/1538-7445.AM2015-1979